Memo Therapeutics
Memo Therapeutics AG is a Swiss biotech developing therapeutic antibodies from elite human immune responders using its proprietary DROPZYLLA® single-cell platform, with lead asset potravitug in Phase II/III for BK polyomavirus infection in kidney transplant recipients and additional programs in oncology and recombinant polyclonal IgG.
- Company typePrivate
- Founded2014
- HeadquartersSchlieren, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Memo Therapeutics does
Memo Therapeutics AG is a privately held Swiss biotechnology company headquartered in Schlieren (Zurich), founded in 2014 by Christoph Esslinger. The company develops therapeutic antibodies derived from natural immune responses in elite responders to viral infections and cancer, using its proprietary DROPZYLLA® platform — a microfluidic single-cell engine that copies antibody genetic information from human B cells into immortal cell lines, achieving greater than 80% immune repertoire coverage compared to under 1% for conventional approaches.
Its lead asset, potravitug, is a highly potent human BK polyomavirus (BKPyV)-neutralizing monoclonal antibody in Phase II/III development for treatment of BKPyV infection in kidney transplant recipients, a population of approximately 20% of transplant patients within one year and up to 50% over the lifetime of the transplanted kidney, with no approved disease-modifying therapy. Potravitug has received FDA Fast Track designation (May 2023) and EU Orphan Drug Designation (December 2025). The Phase II SAFE KIDNEY II trial enrolled 95 patients across 22 U.S. sites, with complete data presented at the American Transplant Congress in June 2026 and pivotal Phase III initiation planned for 2026.
The company operates a secondary oncology program mining tumor-infiltrating B-cell repertoires from elite cancer responders, with a discovery collaboration with Ono Pharmaceutical, and a recombinant polyclonal IgG platform partnered with CSL in a deal announced February 2026 with up to CHF 265 million in potential milestones plus single-digit royalties. Memo Therapeutics is pre-commercial, generating no product revenue; its income is limited to R&D funding, technology access fees, and contingent milestone payments from partners. Capital is sourced from a venture-backed investor base including Pureos Bioventures, Ysios Capital, Kurma Partners, Swisscanto, Vesalius Biocapital, and Adjuvant Capital, with cumulative Series C funding of approximately CHF 46 million and a leadership team being deliberately expanded with senior commercial and clinical operations executives ahead of Phase III readiness.
Memo Therapeutics firmographics
Firmographics- Name
- Memo Therapeutics
- Legal name
- Memo Therapeutics AG
- Website
- https://memo-therapeutics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Memo Therapeutics AG is a Swiss biotech developing therapeutic antibodies from elite human immune responders using its proprietary DROPZYLLA® single-cell platform, with lead asset potravitug in Phase II/III for BK polyomavirus infection in kidney transplant recipients and additional programs in oncology and recombinant polyclonal IgG.
- Ownership category
- akta.pro rank
Memo Therapeutics industry classification
Industry- Product category
- Therapeutic Antibodies
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Memo Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Schlieren
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Memo Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Pharmaceutical Product Sales: Revenue from commercialization of therapeutic antibody products upon regulatory approval. Lead product potravitug targets BKPyV infection in kidney transplant recipients with market potential of up to $2 billion annually.
- Licensing and Milestone Payments: Collaboration with CSL includes R&D funding, technology access fees, and development/sales milestones up to CHF 265 million (USD 328 million) plus single-digit royalties assuming option exercise.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Memo Therapeutics product offering
Product offeringCore offering
Memo Therapeutics AG develops best-in-class therapeutic antibodies derived from natural immunity in elite responders to viral infections and cancer. The lead program is potravitug, a BK polyomavirus-neutralizing monoclonal antibody for treating BKPyV infection in kidney transplant recipients (Phase II/III). The company also operates an oncology program mining tumor-infiltrating B-cell repertoires, a Recombinant Polyclonal IgG Technology platform, and previously developed MTX-COVAB for COVID-19. Underpinning the portfolio is the proprietary DROPZYLLA® microfluidic single-cell antibody discovery platform.
Product overview
Memo Therapeutics AG is a late-stage biotech company developing best-in-class therapeutic antibodies based on natural immunity in elite responders to treat viral infections and cancer. The company's lead product is potravitug, a BK polyomavirus-neutralizing monoclonal antibody for kidney transplant recipients, currently in Phase II/III development. Underpinning the portfolio is the proprietary DROPZYLLA® technology platform, a high-throughput microfluidic single-cell antibody discovery system. The company also operates an oncology program developing antibodies from tumor-infiltrating B-cells, a recombinant polyclonal IgG technology platform, and previously developed MTX-COVAB for COVID-19. The company has partnerships with CSL for recombinant polyclonal IgG development and Ono Pharmaceutical for oncology antibody discovery.
Differentiator
Problem solved
Functional benefit
Products and services
- Potravitug (AntiBKV) A highly potent human BK polyomavirus (BKPyV)-neutralizing monoclonal antibody that binds to the VP1 capsid protein and blocks viral attachment to target cells. Developed for treating BKPyV infection in adult kidney transplant recipients, where it has demonstrated sustained reduction in viral load and biopsy-proven resolution of BKPyV-associated nephropathy. In Phase II/III development with FDA Fast Track and EU Orphan Drug designations.
- DROPZYLLA® Antibody Discovery Platform Proprietary microfluidic-based single-cell antibody repertoire copying engine that extracts antibody genetic information from B cells and copies it into robust immortal cells for screening. Creates near-complete human antibody repertoires (greater than 80% coverage versus less than 1% for conventional approaches) and enables iterative high-throughput functional screening of recombinant antibody libraries for viral infections and cancer. Licensed for partnership use, including under the CSL collaboration.
- Oncology Program (Tumor-Infiltrating B-cell Antibody Discovery)
Companies that use Memo Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Memo Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Memo Therapeutics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, secondary and supporting.
- CSLcoreStrategic collaboration and exclusive option-to-license agreement for development of recombinant polyclonal IgG technology using proprietary DROPZYLLA® platform. MTx will develop recombinant polyclonal IgG products receiving R&D funding, technology access fees, and assuming option exercise, milestones and license fees totalling up to CHF 265 million (USD 328 million) plus single-digit royalties. Collaboration combines CSL's global leadership in immunoglobulins with MTx's recombinant polyclonal technology.
- Ono PharmaceuticalsecondaryCollaboration to use DROPZYLLA® technology to discover antibodies for immuno-oncology targets. Pharma partners value MTx's ability to move projects quickly and get results fast, with ability to see project development in real time.
- Vakzine Project Management GmbH (VPM)supportingBased in Hannover, Germany, responsible for translational project management and clinical trial oversight.
- Accelagen Pty LtdsupportingBased in Melbourne, Australia, responsible for clinical trial management.
- TFS HealthSciencesupportingHeadquartered in Lund, Sweden with subsidiaries in Europe and North America. Responsible for clinical trial management.
- Northwestern UniversitysupportingResearch partnership for qualitative study on impact of BK polyomavirus on health-related quality of life in kidney transplant recipients. Published in Journal of Patient-Reported Outcomes.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Memo Therapeutics competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Memo Therapeutics social profiles
Digital presenceMemo Therapeutics compliance and trust
Trust signalCompliance2 records
Memo Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Memo Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Memo Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Memo Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Memo Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Memo Therapeutics
What does Memo Therapeutics do?
Memo Therapeutics AG develops best-in-class therapeutic antibodies derived from natural immunity in elite responders to viral infections and cancer. The lead program is potravitug, a BK polyomavirus-neutralizing monoclonal antibody for treating BKPyV infection in kidney transplant recipients (Phase II/III). The company also operates an oncology program mining tumor-infiltrating B-cell repertoires, a Recombinant Polyclonal IgG Technology platform, and previously developed MTX-COVAB for COVID-19. Underpinning the portfolio is the proprietary DROPZYLLA® microfluidic single-cell antibody discovery platform.
Is Memo Therapeutics a public or private company?
Memo Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Memo Therapeutics founded?
Memo Therapeutics was founded in 2014. It employs 11 to 50 people.
Where is Memo Therapeutics based?
Memo Therapeutics is headquartered in Schlieren, Switzerland, in the Europe region.
How does Memo Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Milestone Payments.
Does Memo Therapeutics have an API?
No public API is recorded for Memo Therapeutics.
What industry is Memo Therapeutics in?
Memo Therapeutics's product category is Therapeutic Antibodies. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.